Systemic lupus erythematosus and the eye

Alastair K.O. Denniston; Erika M. Damato; Philip I. Murray

doi:10.1016/B978-0-12-801917-7.00049-8

Systemic lupus erythematosus and the eye

Alastair K.O. Denniston^*, Erika M. Damato, Philip I. Murray

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Ocular involvement is common in systemic lupus erythematosus (SLE), ranging from relatively mild dry eye syndrome to severe sight-threatening disease. The recognition of ocular manifestations is important in the treatment of ocular disease and may indicate underlying active systemic inflammation. Ophthalmic sequelae may also arise from the systemic treatments required for the treatment of SLE.

Original language	English
Title of host publication	Systemic Lupus Erythematosus
Subtitle of host publication	Basic, Applied and Clinical Aspects
Editors	George C. Tsokos
Publisher	Elsevier
Chapter	49
Pages	431-439
Number of pages	9
ISBN (Electronic)	9780128020098
ISBN (Print)	9780128019177
DOIs	https://doi.org/10.1016/B978-0-12-801917-7.00049-8
Publication status	Published - 1 Jan 2016

Keywords

Dry eye syndrome
Hydroxychloroquine
Keratoconjunctivitis sicca
Toxic retinopathy

ASJC Scopus subject areas

Medicine(all)
Immunology and Microbiology(all)

Access to Document

10.1016/B978-0-12-801917-7.00049-8Licence: None: All rights reserved

Cite this

@inbook{40b4cdf2121f429988b79f79d590a5e4,

title = "Systemic lupus erythematosus and the eye",

abstract = "Ocular involvement is common in systemic lupus erythematosus (SLE), ranging from relatively mild dry eye syndrome to severe sight-threatening disease. The recognition of ocular manifestations is important in the treatment of ocular disease and may indicate underlying active systemic inflammation. Ophthalmic sequelae may also arise from the systemic treatments required for the treatment of SLE.",

keywords = "Dry eye syndrome, Hydroxychloroquine, Keratoconjunctivitis sicca, Toxic retinopathy",

author = "Denniston, {Alastair K.O.} and Damato, {Erika M.} and Murray, {Philip I.}",

year = "2016",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-801917-7.00049-8",

language = "English",

isbn = "9780128019177",

pages = "431--439",

editor = "{C. Tsokos}, {George }",

booktitle = "Systemic Lupus Erythematosus",

publisher = "Elsevier",

}

TY - CHAP

T1 - Systemic lupus erythematosus and the eye

AU - Denniston, Alastair K.O.

AU - Damato, Erika M.

AU - Murray, Philip I.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Ocular involvement is common in systemic lupus erythematosus (SLE), ranging from relatively mild dry eye syndrome to severe sight-threatening disease. The recognition of ocular manifestations is important in the treatment of ocular disease and may indicate underlying active systemic inflammation. Ophthalmic sequelae may also arise from the systemic treatments required for the treatment of SLE.

AB - Ocular involvement is common in systemic lupus erythematosus (SLE), ranging from relatively mild dry eye syndrome to severe sight-threatening disease. The recognition of ocular manifestations is important in the treatment of ocular disease and may indicate underlying active systemic inflammation. Ophthalmic sequelae may also arise from the systemic treatments required for the treatment of SLE.

KW - Dry eye syndrome

KW - Hydroxychloroquine

KW - Keratoconjunctivitis sicca

KW - Toxic retinopathy

UR - http://www.scopus.com/inward/record.url?scp=84967103671&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-801917-7.00049-8

DO - 10.1016/B978-0-12-801917-7.00049-8

M3 - Chapter

AN - SCOPUS:84967103671

SN - 9780128019177

SP - 431

EP - 439

BT - Systemic Lupus Erythematosus

A2 - C. Tsokos, George

PB - Elsevier

ER -

Systemic lupus erythematosus and the eye

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this